Transdiagnostic and Transcultural: Pilot Study of Unified Protocol for Depressive and Anxiety Disorders in Japan. Issue 3 (May 2016)

• Record Type: Journal Article
• Authors: Ito, Masaya; Horikoshi, Masaru; Kato, Noriko; Oe, Yuki; Fujisato, Hiroko; Nakajima, Shun; Kanie, Ayako; Miyamae, Mitsuhiro; Takebayashi, Yoshitake; Horita, Ryo; Usuki, Masato; Nakagawa, Atsuo; Ono, Yutaka
• Is Part Of: Behavior therapy. Volume 47:Issue 3(2016)
• Page Start: 416
• Page End: 430
• Publication Date: 2016-05
• Subjects: anxiety disorder -- cognitive behavioral therapy -- culture -- depressive disorder; Behavior therapy -- Periodicals; 616.8914205
• DOI: 10.1016/j.beth.2016.02.005
• Languages: English
• ISSNs: 0005-7894

Abstract

Abstract: Unified protocol (UP) is a transdiagnostic cognitive behavior therapy for emotional disorders. It remains unknown whether UP is applicable for use in non-Western countries and for depressive disorders. We therefore examined its feasibility for a Japanese clinical population using this clinical trial design, which is multicentered, open-labeled, and single-armed (Clinical registry: UMIN000008322). The primary outcome was severity of anxiety symptoms, as assessed using Structured Interview Guide for the Hamilton Anxiety Rating Scale. Secondary outcomes were depressive symptoms, clinical global impression, functioning, quality of life, affectivity, emotion regulation, and adverse events. Of the 28 prospective participants, 17 were eligible and enrolled (depressive disorders = 9, anxiety disorders = 8). Severity of anxiety symptoms, which decreased significantly after the intervention, remained low for 3 months (Hedges' g = 1.29, 95% CI = 0.56–2.06). Similar tendencies were observed for secondary outcome measures. No severe adverse event occurred. Two participants dropped out of the intervention. High treatment adherence and interrater reliability were confirmed. Results suggest the feasibility of UP in the Japanese context sufficient to warrant a larger clinical trial. Highlights: Unified protocol is a transdiagnostic treatment for emotional disorders. Unified protocol and its clinical trial are feasible for non-Western countries. Potential efficacy exists for anxiety, depression, and clinical global impression. No severe adverse event was observed during treatment. Effects of Unified Protocol on suppression might differ cross-culturally.